Year 2020 / Volume 112 / Number 2
Original
Megacolon in inflammatory bowel disease: response to infliximab

90-93

DOI: 10.17235/reed.2020.6394/2019

Andrea Núñez Ortiz, Claudio Trigo Salado, María Dolores de la Cruz Ramírez, José Luis Márquez Galán, José Manuel Herrera Justiniano, Eduardo Leo Carnerero,

Abstract
Megacolon is a serious complication of inflammatory bowel disease that often requires a colectomy. Infliximab is a therapeutic alternative when conventional treatment fails, before resorting to surgery. Its use is currently based on the publication of isolated cases. We present a series of 12 patients with megacolon treated with infliximab, five with signs of systemic toxicity. Seventy-five percent of the patients avoided a colectomy during their acute episode after early infliximab treatment, 2.45 days after the megacolon diagnosis. There was a greater risk of surgery among patients with ulcerative colitis and toxicity criteria. Two more patients required follow-up surgery despite long-term infliximab treatment. No patient suffered significant treatment-related adverse effects or significant post-surgery complications.
Share Button
New comment
Comments
No comments for this article
References
1. Sheth SG, LaMont JT. Toxic megacolon. Lancet 1998 Feb 14; 351(9101): 509-13.
2. Harbord M, Eliakim R, Bettenworth D et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohn Colitis 2017;11(7):769-84.
3. Jalan KN, Circus W, Cord WI. An experience with ulcerative colitis: toxic dilatation in 55 cases. Gastroenterology 1969;57:68-82.
4. Sobrado CW, Sobrado LF. Management of acute severe ulcerative colitis: a clinical update. Arg Bras Cir Dig 2016 Jul-Sep; 29(3): 201-5.
5. Criscuoli V, Rizzuto MR, Gallo E et al. Toxic megacolon and human Cytomegalovirus in a series of severe ulcerative colitis patients. J Clin Virol 2015 May; 55: 103-6.
6. Mourelle M, Casellas F, Guarner F et al. Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon. Gastroenterology 1995 Nov; 109 (5): 1497-502.
7. Grieco MB, Bordan DL, Geiss AC et al. Toxic megacolon complicating Crohn´s colitis. Ann Surg 1980 Jan; 191 (1): 75-80.
8. Strong SA. Management of acute colitis and toxic megacolon. Clin Colon Rectal Surg 2010 Dec; 23 (4) 274-84.
9. Castro Fernández M, García Romero D, Sánchez Muñoz D et al. Sevre ulcerative colitis, whit toxic megacolon, resolved whit infliximab theraphy. Rev Esp Enferm Dig 2007 Jul; 99 (7): 426-7.
10. Lee KM, Kim JS, Shin DH et al. Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication. Korean J Gastroenterol 2004 Nov, 44 (5): 259-66.
11. Van Geenen EJ, Sachar DB. Infliximab in Crohn´s disease-associated toxic megacolon. J Clin Gastroenterol 2012 Apr; 46 (4): 321-3.
Related articles

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Letter to the Editor

Acute colonic complications in a patient with Chagas disease

DOI: 10.17235/reed.2016.4193/2016

Citation tools
Núñez Ortiz A, Trigo Salado C, de la Cruz Ramírez M, Márquez Galán J, Herrera Justiniano J, Leo Carnerero E, et all. Megacolon in inflammatory bowel disease: response to infliximab. 6394/2019


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1436 visits.
This article has been downloaded 277 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 21/05/2019

Accepted: 26/07/2019

Online First: 21/01/2020

Published: 07/02/2020

Article revision time: 62 days

Article Online First time: 245 days

Article editing time: 262 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology